Elizabeth Berry-Kravis to Receptor, Metabotropic Glutamate 5
This is a "connection" page, showing publications Elizabeth Berry-Kravis has written about Receptor, Metabotropic Glutamate 5.
Connection Strength
1.225
-
Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome. PLoS One. 2019; 14(1):e0209984.
Score: 0.689
-
Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. Neuropsychopharmacology. 2018 02; 43(3):503-512.
Score: 0.156
-
Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs. 2014 Jan; 23(1):125-34.
Score: 0.121
-
Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ. 2012; 54:297-335.
Score: 0.106
-
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009 Apr; 46(4):266-71.
Score: 0.086
-
Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Sci Rep. 2018 11 19; 8(1):16970.
Score: 0.043
-
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011 Jan 05; 3(64):64ra1.
Score: 0.025